The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.
CITATION STYLE
Lamberti, M. J., Nigro, A., Mentucci, F. M., Vittar, N. B. R., Casolaro, V., & Col, J. D. (2020). Dendritic cells and immunogenic cancer cell death: A combination for improving antitumor immunity. Pharmaceutics, 12(3). https://doi.org/10.3390/pharmaceutics12030256
Mendeley helps you to discover research relevant for your work.